stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Book value per share
Ionis Pharmaceuticals, Inc.'s book value per share at the end of fiscal 2025 was 3.1×, down 22.3% from 3.9× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 2.7×. Over the past ten years it has ranged from 0.8× (fiscal 2016) to 12.0× (fiscal 2019); the current reading is higher than 45% of that period. Ionis Pharmaceuticals, Inc. ranks 237th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 3.1× | (22.32%) |
| FY2024 | 3.9× | 45.72% |
| FY2023 | 2.7× | (33.13%) |
| FY2022 | 4.0× | (26.20%) |
| FY2021 | 5.5× | 2.79% |
| FY2020 | 5.3× | (55.75%) |
| FY2019 | 12.0× | 34.12% |
| FY2018 | 9.0× | 204.61% |
| FY2017 | 2.9× | 257.76% |
| FY2016 | 0.8× | (50.91%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 2.7× | (10.81%) |
| Mar 2026 | 3.0× | (2.49%) |
| Dec 2025 | 3.1× | (20.98%) |
| Sep 2025 | 3.9× | (2.56%) |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 48.2× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 19.3× |
| ORKA Oruka Therapeutics, Inc. compare | 17.7× |
| CGON CG Oncology, Inc. compare | 11.7× |
| IMVT Immunovant, Inc. compare | 3.6× |
| IONS Ionis Pharmaceuticals, Inc. | 2.7× |
| AXSM Axsome Therapeutics, Inc. compare | 2.0× |
| KOD Kodiak Sciences Inc. compare | 1.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | −0.8× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement